Having considered the comments and recommendations of the Sub-Committee on Project Review (UNEP/OzL.Pro/ExCom/38/14, paragraphs 97 and 98), the Executive Committee decided:
(a) To take note of the Government of Cuba’s transitional strategy to non-CFC MDIs and the associated investment project for the phase-out of CFCs used in the manufacture of MDIs at Laboratorio Farmaceutico Julio Trigo Lopez;
(b) To note that the capital cost of the project, as revised, amounts to US $1,488,000 (including US $430,000 for trials, pilot scale production, clinical trials, product stability, technical supervision, inspections and certification of completion);
(c) To request UNDP to continue assisting the Government of Cuba in finalization of the transitional strategy and the identification of a potential provider of the HFC-134a MDI technology and resubmit the transitional strategy and the investment project once a provider has been identified and selected by the Government of Cuba to the 39th meeting of the Executive Committee;
(d) To maintain the transitional strategy to non-CFC MDIs and the investment project for the phase-out of CFCs in MDIs in Cuba in the 2002 UNDP business plan;
(e) To note the importance of the project for Cuba and commend the efforts of Cuba, the Secretariat, and UNDP directed to achieving the transfer of the required technology;
(f) To further request that those efforts be maintained with a view to having the resubmission, referred to in subparagraph (c) above, take place at the 39th meeting of the Executive Committee.